Canaccord Raises Price Target on AbbVie Following Apogee Acquisition

Following AbbVie’s acquisition of Apogee Therapeutics, Canaccord raised its price target for AbbVie from $265 to $273 and reiterated a Buy rating. The firm believes the deal strengthens AbbVie's long-term growth prospects by adding a potential blockbuster immunology asset.

By Vardah Gill Thu, June 25, 2026 at 6:35 AM GMT+3 2 min read · Yahoo Finance · June 25, 2026, 03:35 UTC

Canaccord Raises Price Target on AbbVie Following Apogee Acquisition

Tickers: $ABBV $APGE

Topics: Biotech Mergers & Acquisitions Investment Research Pharmaceuticals

Read the full article at Yahoo Finance

More World news

Jensen Huang Resigns as Nvidia CEO Amid Personal Conduct Controversies and China Export Investigations Motley Fool · November 12, 2026, 18:56 UTC
The Adecco Group Reports Q3 2026 Growth Driven by Temporary Staffing and Margin Expansion PR Newswire · November 12, 2026, 18:54 UTC
Twist Bioscience Projects FY2027 Revenue Between $550M and $560M Seeking Alpha · November 12, 2026, 18:50 UTC
Dixie Group Reports Q3 Sales Growth Amid Margin Pressure and Future Cost-Reduction Targets Seeking Alpha · November 12, 2026, 18:50 UTC
Data I/O Corporation Targets Rapid V-TEK Synergy Realization Amid $80 Million M&A Pipeline Seeking Alpha · November 12, 2026, 18:50 UTC
Leatt Corporation Reports 43% Increase in Q3 Revenue to $20.46 Million Seeking Alpha · November 12, 2026, 18:50 UTC
Parsons Reports Strong Third Quarter Results Driven by High-Margin Product Shift Motley Fool · November 12, 2026, 18:45 UTC
C.H. Robinson Reports Q3 2026 Earnings Driven by AI Efficiency and Margin Expansion Motley Fool · November 12, 2026, 18:45 UTC
Baker Hughes Raises Guidance Amid Surging Data Center Power Demand Motley Fool · November 12, 2026, 18:45 UTC
California Supreme Court to Rule on Insurance Overcharge Liability Under Proposition 103 PR Newswire · November 12, 2026, 18:44 UTC